<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674866</url>
  </required_header>
  <id_info>
    <org_study_id>NN1250-4396</org_study_id>
    <secondary_id>U1111-1203-7872</secondary_id>
    <nct_id>NCT03674866</nct_id>
  </id_info>
  <brief_title>A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus</brief_title>
  <acronym>CAN-TREAT</acronym>
  <official_title>A Canadian Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus CAN-TREAT (CANadian TREsiba AudiT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect historical data in real life conditions in a large
      group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin
      degludec) for at least 6 months. Data will be collected beginning 6 months before the
      participant started Tresiba® up to around 6 months after the participant started taking
      insulin degludec.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Actual">April 26, 2019</completion_date>
  <primary_completion_date type="Actual">April 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycated Haemoglobin (HbA1c)</measure>
    <time_frame>Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec</time_frame>
    <description>measured in % point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in percentage of patients with HbA1c below 7%</measure>
    <time_frame>Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec</time_frame>
    <description>percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percentage of patients with HbA1c below 7.5%</measure>
    <time_frame>Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec</time_frame>
    <description>percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percentage of patients with HbA1c below 8.0%</measure>
    <time_frame>Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec</time_frame>
    <description>percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec</time_frame>
    <description>measured in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin degludec dose</measure>
    <time_frame>At switch to insulin degludec (week 0)</time_frame>
    <description>measured in units/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin degludec dose</measure>
    <time_frame>6 months after switch to insulin degludec</time_frame>
    <description>measured in units/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the mean daily insulin doses (total, basal, prandial)</measure>
    <time_frame>Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec</time_frame>
    <description>measured in units/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of concomitant non-insulin glucose-lowering drug classes</measure>
    <time_frame>Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec</time_frame>
    <description>number of concomitant non-insulin glucose-lowering drug classes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline (up to 3 months prior to switch), 6 months after switch to insulin degludec</time_frame>
    <description>measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of patients with at least one hypoglycaemic episode (overall, nonsevere,non-severe)</measure>
    <time_frame>Before change to insulin degludec (-6 to 0 months)</time_frame>
    <description>percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of patients with at least one hypoglycaemic episode (overall, nonsevere,non-severe)</measure>
    <time_frame>After change to insulin degludec (0 to 6 months)</time_frame>
    <description>percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the rates of hypoglycaemic episodes (overall, non-severe, severe, nocturnal)</measure>
    <time_frame>Before change to insulin degludec (-6 to 0 months)</time_frame>
    <description>rates of hypoglycaemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the rates of hypoglycaemic episodes (overall, non-severe, severe, nocturnal)</measure>
    <time_frame>After change to insulin degludec (0 to 6 months)</time_frame>
    <description>rates of hypoglycaemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients continuing insulin degludec</measure>
    <time_frame>After change to insulin degludec (0 to 6 months)</time_frame>
    <description>percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason(s) for starting insulin degludec</measure>
    <time_frame>At time of switch to insulin degludec (week 0)</time_frame>
    <description>Reasons for starting insulin degludec (if available) will be classified as: Not at glycaemic target, Hypoglycaemia (severe / non-severe / nocturnal), Hypoglycaemia unawareness, Multiple risk factors for hypoglycaemia (elderly, intensive exercise, Chronic Kidney Disease, other), Basal insulin dose more than 80 units/day, Twice daily basal insulin dosing, Fasting blood glucose variability, Need for flexible time of dosing, Device issue, other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason(s) for discontinuing insulin degludec</measure>
    <time_frame>At time of discontinuing insulin degludec (0 to 6 months)</time_frame>
    <description>Reasons for discontinuing insulin degludec (if applicable and available) will be classified as: Injection site reaction, Insufficient efficacy, Hypoglycaemia (severe / non-severe / nocturnal), Weight gain, Cost, Device issue, Other</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">662</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patients with diabetes</arm_group_label>
    <description>Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin degludec</intervention_name>
    <description>Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.</description>
    <arm_group_label>Patients with diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 1 or type 2 diabetes mellitus whose basal insulin was switched to
        insulin degludec
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent will be obtained before any study-related activities. Study-related
             activities are any data collection from the medical records of the patient

          -  Male or female age greater than or equal to 18 years at the time of insulin degludec
             initiation

          -  Type 1 diabetes mellitus or insulin-treated type 2 diabetes mellitus patients

          -  Switched to insulin degludec (± prandial insulin) after any basal insulin (± prandial
             insulin). Switch must have occurred at least 6 months prior to data collection and the
             patient may or may not be treated with insulin degludec at the time of patient
             selection

          -  Previously treated with any basal insulin (± prandial insulin) for at least 6 months
             prior to switching to insulin degludec

          -  At least one documented medical visit in the first 6 months (closest value in 3 to 9
             months window) after insulin degludec initiation

          -  Minimum available data at the time of insulin degludec initiation: age, type of
             diabetes, HbA1c, duration of diabetes, duration and type of insulin treatment, medical
             follow-up at the study site for at least 1 year, and an estimated glomerular
             filtration rate (eGFR) value in the last 12 ±6 months (full data period)

        Exclusion Criteria:

          -  Previous participation in this study. Participation is defined as having signed the
             Informed Consent in this study

          -  Patients treated by continuous subcutaneous insulin infusion or premix insulin in the
             6 months prior to receiving Tresiba
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2H 2G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5T 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6J 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shubenacadie</city>
        <state>Nova Scotia</state>
        <zip>B2T 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1P 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1Z 0M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6S 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>Ontario</state>
        <zip>L4K 4M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9R 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 3R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 7P2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3S 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nepean</city>
        <state>Ontario</state>
        <zip>K2J 0V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Orillia</city>
        <state>Ontario</state>
        <zip>L3V 2Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1E 5E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <zip>K7A 4W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tecumseh</city>
        <state>Ontario</state>
        <zip>N8N 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6G 1M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 2C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4T 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pierrefonds</city>
        <state>Quebec</state>
        <zip>H8Z 1W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Terrebonne</city>
        <state>Quebec</state>
        <zip>J6X 4P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

